Tirzepatide Once Weekly for the Treatment of Obesity.
High Confidence RCTPrimary source: [Open]
Linked compounds: tirzepatide
Outcomes summary
Randomized, placebo-controlled trial evaluating multiple once-weekly tirzepatide doses in adults with obesity; higher doses produced greater weight loss than placebo, with gastrointestinal adverse events commonly reported.
Limitations
Trial duration and population may limit generalizability; results depend on dose-escalation and adherence; longer-term safety and hard outcomes require additional evidence.
Notes
Primary source: PMID 35658024 (see PubMed link on this page).